Compare American Tower Corp (AMT) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Tower Corp vs Neurocrine Biosciences Inc — how do they compare? American Tower Corp trades at $170.25 (market cap $79.00B), while Neurocrine Biosciences Inc trades at $156.39 (market cap $16.46B). The key difference: American Tower Corp is far larger — about 4.8× Neurocrine Biosciences Inc's market cap, and American Tower Corp pays a 4.12% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| AMT | NBIX | |
|---|---|---|
Market Cap | $79.00B | $16.46B |
Sector | Real Estate | Health |
52-Week High | $211.88 | $185.50 |
52-Week Low | $162.11 | $123.10 |
Enterprise Value | $122.53B | $16.48B |
Dividend Yield | 4.12% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
American Tower Corporation (AMT) trades at $171.4, up 1.35% over the past 24 hours, with a bearish technical signal from moving averages but strong fundamental performance. The company reported Q2 2026 earnings beats, with EPS of $1.86 versus $1.57 expected, and maintains robust profitability margins, including a net income margin of 26.81%. Recent news highlights accelerated lease contract growth and a positive analyst consensus.
The outlook for AMT is supported by solid earnings growth and a 27.3% upside to the consensus price target of $206.17, though risks include interest rate sensitivity and high debt levels. Investment appeal hinges on execution in telecom infrastructure and data center expansion, balanced against macroeconomic pressures.
Neurocrine Biosciences (NBIX) trades at $156.95, down 4.83% in the last session, with a bearish technical signal from moving averages and ADX. The stock shows strong fundamentals, including a 39% year-over-year revenue growth in Q2 2026 to $959 million and a net income margin of 20.91% for 2026. Recent developments include positive INGREZZA clinical data and the initiation of a Phase 1 study for a GLP-1/GIP/glucagon receptor triple agonist, though safety concerns were raised for Vykat XR in Prader-Willi Syndrome.
The outlook for NBIX is positive with a consensus price target of $208.82, implying 33% upside, supported by robust earnings beats and portfolio expansion. Risks include drug safety issues, competitive pressures, and reliance on INGREZZA sales. Investors should weigh strong analyst bullishness against regulatory and execution risks in the biopharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Tower Corp
American Tower owns and operates more than 220,000 cell towers throughout the U.S., Asia, Latin America, Europe, and Africa. It also owns and/or operates 25 data centers in eight U.S. markets after acquiring CoreSite. On its towers, the company has a very concentrated customer base, with most revenue in each market being generated by just the top few mobile carriers. The company operates more than 40,000 towers in the U.S., which accounted for more than half of its total revenue in 2021. Outside the U.S., American Tower's greatest presence is in India and Brazil, where it operates roughly 75,000 and 19,000 towers, respectively. American Tower operates as a real estate investment trust.
Read more on AMT →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
